CVE:KSI
Kneat.com Inc (KSI.V)
Financials 
Technical Analysis 
Jul 22, 2026, 12:00 amThis summary was created by AI, based on 2 opinions in the last 12 months.
Kneat.com Inc (KSI-X) is currently viewed as a promising investment opportunity, highlighted by its recent designation as a Top Pick along with a significant buyout offer of $6.50 from private equity shareholders. The company's innovative digital cloud platform, aimed at replacing traditional medical paperwork, positions it favorably despite recent challenges. Analysts emphasize the need for execution following two consecutive quarters of slight revenue misses, which have dampened share performance temporarily. Nonetheless, the general sentiment remains optimistic; analysts predict a recovery with a price target of $6.60, indicating a potential upside. The upcoming shareholder vote on July 30 regarding the buyout adds an element of intrigue for current and prospective investors.
We like KSI, and we even covered the name in one of our latest podcast episodes (link to our discussion on KSI can be found here).
KSI is a $630M healthcare SaaS company that provides solutions for data and document management. Good sales growth is expected over the next few years, although it is not yet profitable. It generates positive free cash flows, has a strong balance sheet, strong gross margins, and we feel it is at the turning point of becoming profitable. Overall, we like the name and have it in our Growth model portfolio.
Unlock Premium - Try 5i Free
Rare to find a high-quality, small-cap tech company in Canada with good management. High growth. Grew ARR last quarter by 60%, very impressive. Valuation of 7x may seem high by Canadian standards, but not compared to US peers. Targeting regulated industries that need a validation solution. No dividend.
Has the majority of the big-pharma household names as customers. Delivered on what they said they would over the years. Still quite a bit to go. Selling to both new customers and current installed base, a very good sign. Likes the metrics, management, the market, customer base.
They bring validation software to biopharma, and they do it well. The chart is strong. He's been adding shares. Before, they were losing as they invested in R&D, but now they're becoming profitable. He expects margins to expand quickly in coming years. When they win a client, it takes time to roll out that client. Growth is safe.
Jesse GambleSoftware company that is based in Ireland.
Offers compliance and validation software in life sciences business.
Currently has 8/10 of top pharma & 18/20 top bio-pharma companies as customers.
Growing customer base at a rapid rate.
Very positive on outlook of business.
Will continue to own shares.
- «
- ‹
- 1
- ›
- »
Popular Articles
Kneat.com Inc (KSI.V) Frequently Asked Questions
What is Kneat.com Inc stock symbol?
Kneat.com Inc is a Canadian stock, trading under the symbol KSI.V (previously KSI-X on Stockchase) on the TSX Venture Exchange (KSI-CV). It is usually referred to as TSXV:KSI or KSI.V
Is Kneat.com Inc a buy or a sell?
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on KSI.V (previously KSI-X on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is PAST TOP PICK. Read the latest stock experts' ratings for Kneat.com Inc.
Is Kneat.com Inc a good investment or a top pick?
Kneat.com Inc was recommended as a Top Pick by Michael Hakes - CFA, MBA on 2026-07-03. Read the latest stock experts ratings for Kneat.com Inc.
Why is Kneat.com Inc stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Kneat.com Inc.
Is Kneat.com Inc worth watching?
Kneat.com Inc is followed by 41 investors on Stockchase and is a trending stock that is worth watching.
What is Kneat.com Inc stock price?
On 2021-11-12, Kneat.com Inc (KSI.V) stock closed at a price of $4.25.
(Note the short timeframe.) Taken out. Buyout offer of $6.50 from private equity, shareholder vote on July 30.